The Feasibility of Developing a Universal SARS-CoV-2 Vaccine
Vaccines · 13.03.2026 · 14 (3) · 259
DOI: 10.3390/vaccines14030259 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 13.03.2026. Verfasst von Mohammed Asaad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Basic Medical Sciences Department, College of Medicine, QU Health, Qatar University, Doha 2713, Qatar. Die Arbeit nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar Research, Development and Innovation Council, Qatar Research, Development and Innovation Council, Academic Research.
Abstract (Originalsprache)
As SARS-CoV-2 continues to evolve with increased transmissibility and immune evasion, the need for vaccines that provide broader and more durable protection has become increasingly urgent. The extensive research spurred by the pandemic has accelerated the development of diverse vaccine platforms, including mRNA, DNA, virus-like particles (VLPs), recombinant proteins, and mosaic mono- and polyvalent vaccines. While several of these platforms have reached regulatory approval and widespread clinical employment, others remain under evaluation or in various stages of clinical development. These vaccines have significantly reduced infection rates, severe disease, and hospitalizations, particularly among high-risk group. Nevertheless, the ongoing emergence of novel variants and subvariants has challenged the efficacy of both existing and newly developed vaccines. This evolving landscape underscores the urgent need for a universal SARS-CoV-2 vaccine platform capable of providing comprehensive and long-lasting immunity. In this review, we evaluate current and emerging strategies for SARS-CoV-2 universal vaccine development, with a focus on antigen design, breadth of immune protection, and clinical feasibility. Attention is given to various universal vaccine platforms such as the mosaic polyvalent spike construct, multi-epitope vaccines targeting the receptor-binding domain (RBD), and approaches centered on the conserved S2 subunit of the spike protein. We also discuss strategies leveraging additional conserved viral proteins and T helper (Th) and cytotoxic T lymphocyte (CTL) epitopes from across coronaviruses. By highlighting the advances in these areas, this review provides a framework to guide the rational design of next-generation universal vaccines capable of delivering broad and durable protection against SARS-CoV-2 variants.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Basic Medical Sciences Department, College of Medicine, QU Health, Qatar University, Doha 2713, Qatar.
- School of Medicine, Wayne State University, Detroit, MI 48201, USA.
- Hamad Medical Corporation, Doha 3050, Qatar.
- Biomedical Research Centre, QU Health, Qatar University, Doha 2713, Qatar.
ORCID-Profile: Hadi M Yassine, Abdallah M Abdallah
Förderung
- Qatar Research, Development and Innovation Council
- Qatar Research, Development and Innovation Council, Academic Research
Zitieren
APA
Asaad, M., Mustafa, M. O., Al-Haneedi, Y., Shalaby, L., Shams Eldin, R., Mohamedahmed, Y., Yassine, H. M., Abdallah, A. M., & Emara, M. M. (2026). The Feasibility of Developing a Universal SARS-CoV-2 Vaccine. Vaccines, 14(3), 259. https://doi.org/10.3390/vaccines14030259
Vancouver
Asaad M, Mustafa MO, Al-Haneedi Y, Shalaby L, Shams Eldin R, Mohamedahmed Y, et al. The Feasibility of Developing a Universal SARS-CoV-2 Vaccine. Vaccines. 2026;14(3):259. doi:10.3390/vaccines14030259
BibTeX
@article{Asaad2026,
author = {Asaad, Mohammed and Mustafa, Mohamed O and Al-Haneedi, Yaman and Shalaby, Lina and Shams Eldin, Rania and Mohamedahmed, Yasar and Yassine, Hadi M and Abdallah, Abdallah M and Emara, Mohamed M},
title = {The Feasibility of Developing a Universal SARS-CoV-2 Vaccine},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {3},
pages = {259},
doi = {10.3390/vaccines14030259}
}
EUVIMED